In comparison, a report of two cases with Castleman's disease (characterized by chronic IL-6 overproduction) showed reduction in hepcidin secretion following treatment with anti-IL-6 receptor antibodies, suggesting that chronic stimulation and/or inflammation may drive inappropriate hepcidin responses and thus ACD [53], [54]. The gene discussed is HAMP; the disease is Castleman disease.